254 related articles for article (PubMed ID: 32511022)
21. Importins and exportins as therapeutic targets in cancer.
Mahipal A; Malafa M
Pharmacol Ther; 2016 Aug; 164():135-43. PubMed ID: 27113410
[TBL] [Abstract][Full Text] [Related]
22. The nuclear export protein XPO1 - from biology to targeted therapy.
Azmi AS; Uddin MH; Mohammad RM
Nat Rev Clin Oncol; 2021 Mar; 18(3):152-169. PubMed ID: 33173198
[TBL] [Abstract][Full Text] [Related]
23. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract][Full Text] [Related]
24. [New European approval: Selinexor for triple class refractory multiple myeloma].
Nsiala L; Chalopin T
Bull Cancer; 2022 Jan; 109(1):6-7. PubMed ID: 34857363
[No Abstract] [Full Text] [Related]
25. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Rosebeck S; Alonge MM; Kandarpa M; Mayampurath A; Volchenboum SL; Jasielec J; Dytfeld D; Maxwell SP; Kraftson SJ; McCauley D; Shacham S; Kauffman M; Jakubowiak AJ
Mol Cancer Ther; 2016 Jan; 15(1):60-71. PubMed ID: 26637366
[TBL] [Abstract][Full Text] [Related]
29. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
[TBL] [Abstract][Full Text] [Related]
30. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
31. XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG; Li Y
J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
[TBL] [Abstract][Full Text] [Related]
32. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
[TBL] [Abstract][Full Text] [Related]
33. The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.
Farren MR; Hennessey RC; Shakya R; Elnaggar O; Young G; Kendra K; Landesman Y; Elloul S; Crochiere M; Klebanov B; Kashyap T; Burd CE; Lesinski GB
Mol Cancer Ther; 2017 Mar; 16(3):417-427. PubMed ID: 28148715
[TBL] [Abstract][Full Text] [Related]
34. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.
Burke RT; Marcus JM; Orth JD
Oncotarget; 2017 Jun; 8(24):39460-39475. PubMed ID: 28467801
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
[TBL] [Abstract][Full Text] [Related]
37. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
Kashyap T; Murray J; Walker CJ; Chang H; Tamir S; Hou B; Shacham S; Kauffman MG; Tripp RA; Landesman Y
Antiviral Res; 2021 Aug; 192():105115. PubMed ID: 34157321
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis.
Shafei L; Bashir S; Chan EW; Abushanab D; Hamad A; Al-Badriyeh D
Curr Probl Cancer; 2024 Jun; 50():101076. PubMed ID: 38537395
[TBL] [Abstract][Full Text] [Related]
39. Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.
Martin JG; Ward JA; Feyertag F; Zhang L; Couvertier S; Guckian K; Huber KVM; Johnson DS
Chembiochem; 2021 Jun; 22(12):2116-2123. PubMed ID: 33887086
[TBL] [Abstract][Full Text] [Related]
40. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
